Literature DB >> 17217311

Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins.

Tsui-Fen Chou1, Janina Baraniak, Renata Kaczmarek, Xin Zhou, Jilin Cheng, Brahma Ghosh, Carston R Wagner.   

Abstract

To facilitate the delivery of nucleotide-based therapeutics to cells and tissues, a variety of pronucleotide approaches have been developed. Our laboratory and others have demonstrated that nucleoside phosphoramidates can be activated intracellularly to the corresponding 5'-monophosphate nucleotide and that histidine triad nucleotide binding proteins (Hints) are potentially responsible for their bioactivation. Hints are conserved and ubiquitous enzymes that hydrolyze phosphoramidate bonds between nucleoside 5'-monophosphate and an amine leaving group. On the basis of the ability of nucleosides to quench the fluorescence of covalently linked amines containing indole, a sensitive, continuous fluorescence-based assay was developed. A series of substrates linking the naturally fluorogenic indole derivatives to nucleoside 5'-monophosphates were synthesized, and their steady state kinetic parameters of hydrolysis by human Hint1 and Escherichia coli hinT were evaluated. To characterize the elemental and stereochemical effect on the reaction, two P-diastereoisomers of adenosine or guanosine phosphoramidothioates were synthesized and studied to reveal a 15-200-fold decrease in the specificity constant (kcat/Km) when the phosphoryl oxygen is replaced with sulfur. While a stereochemical preference was not observed for E. coli hinT, hHint1 exhibited a 300-fold preference for d-tryptophan phosphoramidates over l-isomers. The most efficient substrates evaluated to date are those that contain the less sterically hindering amine leaving group, tryptamine, with kcat and Km values comparable to those found for adenosine kinase. The apparent second-order rate constants (kcat/Km) for adenosine tryptamine phosphoramidate monoester were found to be 107 M-1 s-1 for hHint1 and 106 M-1 s-1 for E. coli hinT. Both the human and E. coli enzymes preferred purine over pyrimidine analogues. Consistent with observed hydrogen bonding between the 2'-OH group of adenosine monophosphate and the active site residue, Asp43, the second-order rate constant (kcat/Km) for thymidine tryptamine phosphoramidate was found to be 3-4 orders of magnitude smaller than that for uridine tryptamine phosphoramidate for hHint1 and 2 orders of magnitude smaller than that for E. coli hinT. Ara-A tryptamine phosphoramidate was, however, shown to be a good substrate with a specificity constant (kcat/Km) only 10-fold lower than the value for adenosine tryptamine phosphoramidate. Consequently, nucleoside phosphoramidates containing unhindered primary amines and either an alpha or beta 2'-OH group should be easily bioactivated by Hints with efficiencies rivaling those for the 5'-monophosphorylation of nucleosides by nucleoside kinases. The differential substrate specificity observed for human and E. coli enzymes represents a potential therapeutic rationale for the development of selective antibiotic phosphoramidate pronucleotides.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17217311     DOI: 10.1021/mp060070y

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  32 in total

1.  Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy.

Authors:  Eisuke Murakami; Ting Wang; Yeojin Park; Jia Hao; Eve-Irene Lepist; Darius Babusis; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 2.  Hits, Fhits and Nits: beyond enzymatic function.

Authors:  Kay Huebner; Joshua C Saldivar; Jin Sun; Hidetaka Shibata; Teresa Druck
Journal:  Adv Enzyme Regul       Date:  2010-10-28

Review 3.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 4.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

5.  Synthesis of 7-benzylguanosine cap-analogue conjugates for eIF4E targeted degradation.

Authors:  Tanpreet Kaur; Arya Menon; Amanda L Garner
Journal:  Eur J Med Chem       Date:  2019-01-31       Impact factor: 6.514

6.  Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.

Authors:  Eisuke Murakami; Ting Wang; Darius Babusis; Eve-Irene Lepist; Dorothea Sauer; Yeojin Park; Jennifer E Vela; Robert Shih; Gabriel Birkus; Dimitrios Stefanidis; Choung U Kim; Aesop Cho; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

7.  Design, Synthesis, and Characterization of Sulfamide and Sulfamate Nucleotidomimetic Inhibitors of hHint1.

Authors:  Rachit Shah; Alexander Strom; Andrew Zhou; Kimberly M Maize; Barry C Finzel; Carston R Wagner
Journal:  ACS Med Chem Lett       Date:  2016-06-15       Impact factor: 4.345

8.  Kinetic mechanism of human histidine triad nucleotide binding protein 1.

Authors:  Xin Zhou; Tsui-Fen Chou; Brandon E Aubol; Chin Ju Park; Richard Wolfenden; Joseph Adams; Carston R Wagner
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

9.  Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation.

Authors:  Brahma Ghosh; Alexey O Benyumov; Phalguni Ghosh; Yan Jia; Svetlana Avdulov; Peter S Dahlberg; Mark Peterson; Karen Smith; Vitaly A Polunovsky; Peter B Bitterman; Carston R Wagner
Journal:  ACS Chem Biol       Date:  2009-05-15       Impact factor: 5.100

10.  Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.

Authors:  Shui Li; Yan Jia; Blake Jacobson; Joel McCauley; Robert Kratzke; Peter B Bitterman; Carston R Wagner
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.